26
|
Ueda A, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Dazai M, Kawahata S, Sasaki T, Sasaki Y, Kato S, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Ando T, Nakano S, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Yoshita H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Sasaki T, Dazai M, Komatsu Y. The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 2019; 29:624-631. [PMID: 29293874 PMCID: PMC5889030 DOI: 10.1093/annonc/mdx816] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab in terms of progression-free survival (PFS). Patients and methods Patients from 53 institutions who had previously untreated mCRC were randomly assigned (1 : 1) to receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; a 3-week regimen: intravenous infusions of irinotecan 150 mg/m2 and bevacizumab 7.5 mg/kg on day 1, oral S-1 80 mg/m2 twice daily for 2 weeks, followed by a 1-week rest; or a 4-week regimen: irinotecan 100 mg/m2 and bevacizumab 5 mg/kg on days 1 and 15, S-1 80 mg/m2 twice daily for 2 weeks, followed by a 2-week rest). The primary end point was PFS. The noninferiority margin was 1.25; noninferiority would be established if the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the control group versus the experimental group was less than this margin. Result Between June 2012 and September 2014, 487 patients underwent randomization. Two hundred and forty-three patients assigned to the control group and 241 assigned to the experimental group were included in the primary analysis. Median PFS was 10.8 months (95% CI 9.6-11.6) in the control group and 14.0 months (95% CI 12.4-15.5) in the experimental group (HR 0.84, 95% CI 0.70-1.02; P < 0.0001 for noninferiority, P = 0.0815 for superiority). One hundred and fifty-seven patients (64.9%) in the control group and 140 (58.6%) in the experimental group had adverse events of grade 3 or higher. Conclusion S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab with respect to PFS as first-line treatment of mCRC and could be a new standard treatment. Clinical trials number UMIN000007834.
Collapse
|
29
|
Kawanami K, Matsuo T, Yuki S, Shimose S, Takahashi R, Deie M. Clinical outcomes of limb salvage surgery with postoperative intensity-modulated radiation therapy for soft-tissue sarcoma and metastasis. Indian J Cancer 2019; 55:176-178. [PMID: 30604732 DOI: 10.4103/ijc.ijc_618_17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE The primary aim of intensity-modulated radiation therapy (IMRT) for treating soft tissue sarcoma of an extremity is the reduction of morbidity and maintenance of local control. METHODS We evaluated the outcomes and toxicity of adjuvant IMRT following function-preserving surgery to treat patients with soft tissue sarcoma and metastasis of the extremities. We retrospectively reviewed prospective databases at Kure Medical Center and Aichi Medical University between 2013 and 2016 and identified 10 patients with lower extremity soft tissue sarcoma who underwent both limb-sparing surgery and postoperative IMRT at one of our institutions. RESULTS There were 7 men and 3 women (mean age, 67.2 years; range, 48-87 years) included in the study. Of these, four patients were continuously disease-free, two showed no evidence of disease, and four died due to disease. The average functional score was 82% (range, 53-100%). Among the 10 patients, 2 (22%) had grade 1-2 edema and 1 (11%) had grade 2 joint stiffness. Another patient developed grade 2 acute dermatitis. There were no severe complications such as infection, tissue necrosis, fracture, or nerve palsy. CONCLUSION Although the number of patients in this study was small, our results show that adjuvant IMRT following function-preserving surgery for soft tissue sarcoma of the extremity can be valuable for treating unmanageable tumors.
Collapse
|
30
|
Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Nakamura M, Muranaka T, Yagisawa M, Kawamoto Y, Yuki S, Ishiguro A, Dazai M, Sogabe S, Harada K, Kobayashi Y, Miyagishima T, Okamura N, Tsuji Y, Terae S, Ono K, Komatsu Y. A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Iwanaga I, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Ito Y, Taketomi A, Hirano S, Sakamoto N, Komatsu Y. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Ishiguro A, Yuki S, Nakano S, Kawamoto Y, Sawada K, Tsuji Y, Honda T, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Yoshikawa A, Kawamoto Y, Yuki S, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Saiki T, Ishiguro A, Saito R, Ehira N, Iwanaga I, Hatanaka K, Abe N, Sakamoto N, Sakata Y, Komatsu Y. HGCSG1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Nakamura M, Yagisawa M, Saiki T, Ishiguro A, Sawada K, Yuki S, Sasaki T, Ando T, Ohori H, Kotaka M, Muto O, Shindo Y, Nakashima K, Hosokawa A, Doi A, Izawa N, Sunakawa Y, Satoh A, Ono K, Komatsu Y. A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Sawada K, Komatsu Y, Muranaka T, Nakano S, Kawamoto Y, Nakatsumi H, Yuki S, Dazai M, Saiki T, Ishiguro A, Tateyama M, Ono K, Ohnishi S, Sakamoto N. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy (MEC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Tsuji Y, Yuki S, Sawada K, Muranaka T, Kobayashi Y, Okuda H, Ogawa K, Minami S, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Saitoh S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Nakamura M, Takashima A, Denda T, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Ohori H, Sekikawa T, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Ishioka C, Shimada K, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T. Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Tokunaga S, Emi Y, Makiyama A, Kawamoto Y, Komatsu Y, Shimokawa M, Saeki H, Oki E, Baba H, Maehara Y. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Shindo Y, Yuki S, Yagisawa M, Kawamoto Y, Tsuji Y, Hatanaka K, Kobayashi Y, Kajiura S, Ishiguro A, Honda T, Dazai M, Eto K, Nakamura M, Koike M, Ota S, Sato A, Kato K, Ueda A, Fukunaga A, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Nakamura M, Komatsu Y, Muranaka T, Yagisawa M, Kawamoto Y, Nakatsumi H, Yuki S, Saiki T, Ishiguro A, Tateyama M, Kobayashi Y, Miyagishima T, Takahata T, Sato A, Dazai M, Okuda H, Fujikawa K, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y. HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Ishiguro A, Kawamoto Y, Yuki S, Nakano S, Yagisawa M, Sawada K, Muranaka T, Hayashi H, Nakatsumi H, Saiki T, Harada K, Kobayashi Y, Iwanaga I, Hatanaka K, Sakata Y, Komatsu Y. HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Bando H, Tsukada Y, Inamori K, Fukuoka S, Sasaki T, Nishizawa Y, Wakabayashi M, Kojima M, Togashi Y, Yuki S, Komatsu Y, Homma S, Hatanaka Y, Matsuno Y, Uemura M, Kato T, Sato A, Nishikawa H, Ito M, Yoshino T. VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Muranaka T, Komatsu Y, Ohnishi S, Yagisawa M, Sawada K, Kawamoto Y, Nakatsumi H, Yuki S, Dazai M, Saiki T, Ishiguro A, Tateyama M, Ono K, Sakamoto N. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Yuki S, Komatsu Y, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Shinohara T, Miyashita K, Ito Y, Taketomi A, Hirano S, Sakamoto N. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Honda T, Yuki S, Muranaka T, Nakatsumi H, Tsuji Y, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Ishiguro A, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Onodera K, Eto K, Tateyama M, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y. First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|